Leerink Partners Reiterates Outperform Rating on Cytokinetics (CYTK) following conference
Tweet Send to a Friend
Leerink Partners analyst Roanna Ruiz reiterated an Outperform rating and $84.00 price target on Cytokinetics (NASDAQ: CYTK)The analyst commented, "Bottom ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
